Foghorn Therapeuticsinc Stock Z Score
| FHTX Stock | USD 5.64 0.37 6.16% |
Foghorn | Z Score |
Foghorn TherapeuticsInc Company Z Score Analysis
Foghorn TherapeuticsInc's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Foghorn Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Foghorn TherapeuticsInc is extremely important. It helps to project a fair market value of Foghorn Stock properly, considering its historical fundamentals such as Z Score. Since Foghorn TherapeuticsInc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Foghorn TherapeuticsInc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Foghorn TherapeuticsInc's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Foghorn TherapeuticsInc has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Foghorn TherapeuticsInc Current Valuation Drivers
We derive many important indicators used in calculating different scores of Foghorn TherapeuticsInc from analyzing Foghorn TherapeuticsInc's financial statements. These drivers represent accounts that assess Foghorn TherapeuticsInc's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Foghorn TherapeuticsInc's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 667.2M | 745.8M | 850.1M | 265.4M | 270.7M | 257.2M | |
| Enterprise Value | 668.8M | 735.0M | 807.3M | (28.9M) | 235.5M | 223.7M |
Foghorn TherapeuticsInc ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Foghorn TherapeuticsInc's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Foghorn TherapeuticsInc's managers, analysts, and investors.Environmental | Governance | Social |
Foghorn TherapeuticsInc Institutional Holders
Institutional Holdings refers to the ownership stake in Foghorn TherapeuticsInc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Foghorn TherapeuticsInc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Foghorn TherapeuticsInc's value.| Shares | Birchview Capital, Lp | 2023-12-31 | 320.9 K | Jacobs Levy Equity Management, Inc. | 2024-03-31 | 216.3 K | Northern Trust Corp | 2023-12-31 | 199.3 K | Sio Capital Management, Llc | 2023-12-31 | 121.7 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 105.1 K | Panagora Asset Management Inc | 2023-12-31 | 97 K | Millennium Management Llc | 2024-03-31 | 62 K | Bank Of New York Mellon Corp | 2023-12-31 | 57.2 K | Charles Schwab Investment Management Inc | 2024-03-31 | 55.4 K | Flagship Ventures Management, Inc. | 2024-03-31 | 12.7 M | Fmr Inc | 2023-12-31 | 2.8 M |
Foghorn Fundamentals
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (2.74) % | ||||
| Operating Margin | (5.58) % | ||||
| Current Valuation | 76.5 M | ||||
| Shares Outstanding | 55.33 M | ||||
| Shares Owned By Insiders | 19.07 % | ||||
| Shares Owned By Institutions | 47.94 % | ||||
| Number Of Shares Shorted | 1.3 M | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 9.25 X | ||||
| Revenue | 34.16 M | ||||
| Gross Profit | (86.39 M) | ||||
| EBITDA | (99.25 M) | ||||
| Net Income | (98.43 M) | ||||
| Cash And Equivalents | 373.5 M | ||||
| Cash Per Share | 8.94 X | ||||
| Total Debt | 45.07 M | ||||
| Debt To Equity | 2.19 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | (2.29) X | ||||
| Cash Flow From Operations | (118.11 M) | ||||
| Short Ratio | 17.41 X | ||||
| Earnings Per Share | (2.20) X | ||||
| Target Price | 13.75 | ||||
| Number Of Employees | 116 | ||||
| Beta | 3.15 | ||||
| Market Capitalization | 312.05 M | ||||
| Total Asset | 285.92 M | ||||
| Retained Earnings | (471.56 M) | ||||
| Working Capital | 181.75 M | ||||
| Net Asset | 285.92 M |
About Foghorn TherapeuticsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Foghorn TherapeuticsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn TherapeuticsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn TherapeuticsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce |
Check out Foghorn TherapeuticsInc Piotroski F Score and Foghorn TherapeuticsInc Valuation analysis. For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn TherapeuticsInc guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Foghorn Stock analysis
When running Foghorn TherapeuticsInc's price analysis, check to measure Foghorn TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn TherapeuticsInc is operating at the current time. Most of Foghorn TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Foghorn TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn TherapeuticsInc's price. Additionally, you may evaluate how the addition of Foghorn TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Foghorn TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn TherapeuticsInc. If investors know Foghorn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Foghorn TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.20) | Revenue Per Share 0.805 | Quarterly Revenue Growth (0.05) | Return On Assets (0.20) | Return On Equity (4.70) |
The market value of Foghorn TherapeuticsInc is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Foghorn TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn TherapeuticsInc's market value can be influenced by many factors that don't directly affect Foghorn TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Foghorn TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Foghorn TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Foghorn TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.